Bolezn' Goshe u detey: osnovnye aspekty
- Authors: Gundobina O.S1
-
Affiliations:
- Issue: No 14 (2013)
- Pages: 70-73
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/282335
- ID: 282335
Cite item
Open Access
Access granted
Abstract
The article presents data on the epidemiology, pathogenesis, modern classification, and major clinical manifestations of Gaucher disease (GD) in children. The criteria of differential diagnosis with other diseases are discussed. It is shown that pathogenetic enzyme replacement therapy is only effective treatment of GD, which stops the main clinical manifestations of the disease, improving quality of life in patients with GD without causing side effects. The monitoring of condition of patients on therapy is recommended in accordance with the requirements of the Joint International Group on Gaucher disease. The main errors of diagnosis and management of these patients, as well as unwarranted use of drugs for the treatment of G, are discussed.
Full Text
References
- Mankin HJ, Rosenthal DI, Xavier R. Gaucher disease. New approaches to an ancient disease. J Bone Joint Surg Am 2001;83A:748-62.
- Koprivica VV, Stone DL, Park JK, et al. Analysis and classification of304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 2000;66(6): 1777-86.
- Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Supp Semin Hematol 2004;41 (5):4-14.
- Andersson H, Kaplan P, Kacena K, et al. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 2008;122(6): 1182-90.
- Weinreb NJ, Taylor J, Cox T, et al. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol 2008;83:890-95.
- Kauli R, Zaizov R, Lazar L, et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/ or enzyme replacement therapy. Isr Med Assoc J 2000;2:158-63.
- Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type I Gaucher disease. JBMR Reprint 2007;22(1):119-26.
- Wenstrup RJ, Roca-Espiau M, Weinreb NJ, et al. Skeletal aspects of Gaucher disease: a review. Br J Radiol 2002;75(1):2-12.
- Bembi В, Ciana G, Mengel E, et al. Bone complications in children with Gaucher disease. Br J Radiol 2002;75(1):37-43.
- Гундобина О.С., Малахов О.О., Морев С.Ю. и др. Развитие костной патологии при болезни Гоше 1-го типа у детей. Клинический пример //Доктор Ру 2011. №(64). С. 10-4.
- Vellodi A, Bembi B, Villemeur TB, et al. Management of neuronopathic Gaucher disease: А European consensus. J Inherit Metab Dis 2001;24:319-27.
- Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004;163(2):67-75.
- Темин П.А., Казанцева Л.З. Наследственные нарушения нервно-психического развития детей: Руководство для врачей. М., 2001. 432 с.
- Краснопольская К.Д. Наследственные болезни обмена веществ. Справочное пособие для врачей. М., 2005. 364 с.
- Grabowski GA, Hopkin RJ. Enzyme therapy for lysosomal storage disease: Principles, practice, and prospects. Annu Rev Genomics Hum Genet 2003;4:403-36.
- Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, Vom Dahl S, Hollak C. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis 2012 Sep 14. [Epub ahead of print].
Supplementary files
